Gabapentin
Product Images NDC 53217-282

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 53217-282). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aidarex Pharmaceuticals Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Equation 1 (Gabapentin 1)

Mathematical formula showing the calculation for creatinine clearance (CLCr) involving age, weight, serum creatinine, and an adjustment factor for female patients. The formula calculates creatinine clearance based on patient demographics and lab values.*

FDA Label Image

Structure (Gabapentin 2)

Chemical structure of gabapentin showing its molecular formula with an amine group (H2N) and a carboxyl group (COOH) attached to a cyclohexane ring.*

FDA Label Image

Fig-1 (Gabapentin 3)

A line graph depicting mean pain scores over an 8-week period, comparing placebo and Gabapentin at 3600 mg/day. The x-axis represents weeks, including a 4-week dose titration period followed by a 4-week fixed dose period. The y-axis shows mean pain scores from 0 to 10, with Gabapentin demonstrating a decreasing trend over time compared to placebo.*

FDA Label Image

Fig-2 (Gabapentin 4)

A line graph showing the mean pain score over 7 weeks comparing placebo, Gabapentin 1800 mg/day, and Gabapentin 2400 mg/day. The x-axis represents weeks with a 3-week dose titration period followed by a 4-week fixed dose period. The y-axis shows mean pain scores, indicating pain reduction trends for the Gabapentin doses versus placebo.*

FDA Label Image

Fig-3 (Gabapentin 5)

A bar chart titled 'Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies' comparing placebo (PBO) and various doses of Gabapentin (GBP 1800, 2400, and 3600 mg). The chart shows percentage responders for two studies, with Gabapentin doses having higher response rates (29% to 34%) than placebo (12% to 14%), including statistical significance markers (p < 0.01 and p < 0.001).*

FDA Label Image

Fig-4 (Gabapentin 6)

A scatter plot comparing the percentage difference against daily dose (mg) for Gabapentin across three studies labeled a, b, and c. The x-axis represents daily dose in milligrams from 600 to 1800 mg, and the y-axis shows percentage difference ranging from 2 to 22%. Study a data points are in black squares, study b in gray squares, and study c in white squares.*

FDA Label Image

Logo (Gabapentin 7)

FDA Label Image

Logo (Gabapentin 8)

FDA Label Image

Image Descriptions (Gabapentin 9)

Gabapentin USP 600 mg film-coated tablets, packaged by Aidarex Pharmaceuticals LLC and manufactured by Glenmark Pharmaceuticals Ltd. The label indicates a quantity of 90 tablets. The label includes dosing instructions and NDC 53217-0282-90, identifying this generic gabapentin product.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.